AI scanned animal venom peptides and found 386 potential antibiotics. Most killed drug-resistant bacteria in tests and were ...

Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

DeepQure is also conducting RDN clinical trials for resistant hypertension in both South Korea and the United States. Patient enrollment is nearing completion domestically, while trials are actively ...

Delays in diagnosis of hypertension are common and associated with delays in treatment initiation, according to a study ...

PFAS, or forever chemicals, can wreak havoc on the body, disrupting hormones and impacting the immune system. Now, ...

A promising new drug may finally bring hope to people suffering from a common but often overlooked cause of high blood ...

Researchers at the German Centre for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of heart failure that has so far been difficult to treat. Prof. Johannes Backs, ...

Game Changers in Nephrology' was the theme of the 62nd European Renal Association (ERA) Congress, held in Vienna, ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...